Transcatheter Market Size

Transcatheter Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The transcatheter market is expected to grow significantly, with a market size of $ 2.26 billion in 2024 and $ 9.23 billion in 2032. This remarkable growth rate, which is to be 16.64% from 2025 to 2032, reflects the growing demand for minimally invasive cardiac surgery. The increasing occurrence of heart disease in combination with an aging population is resulting in a greater need for new and improved treatment options, such as transcatheter devices. Furthermore, technological advancements such as the development of next-generation transcatheter heart valves and improved delivery systems are also expected to drive growth. Edwards Lifesciences and Medtronic are investing heavily in research and development to enhance the performance of their products and thus improve patient outcomes. Strategic initiatives, such as strategic alliances and acquisitions, are also expected to further increase the dynamism of the market. In view of the rapid uptake of these devices by the health care industry, the transcatheter market is expected to transform the landscape of cardiac care.

Regional Market Size

Regional Deep Dive

Transcatheter market is undergoing a significant growth in all the regions of the world, owing to advancements in the field of minimally invasive surgery and the increasing prevalence of cardiovascular diseases. North America leads in the development and application of transcatheter technology, whereas Europe is a region with a well-established regulatory framework that supports the market growth. Asia-Pacific is the fastest-growing region in the market, owing to the increasing healthcare expenditure and the aging population. The Middle East and Africa are adopting these devices at a gradual pace, owing to the development of the healthcare sector. Latin America is also a region that is witnessing a significant growth, owing to the rising awareness about the transcatheter procedures and the increasing investments in the medical technology.

North America

• The Evolut PRO+ and the Sapien 3 Ultra devices have recently been approved by the FDA. They are expected to improve outcomes and expand treatment options.
• In recent years, companies like Medtronic and Edwards Lifesciences have been investing heavily in R&D to improve the safety and effectiveness of these devices.
• The growing occurrence of heart disease, in conjunction with an aging population, has resulted in an increase in the demand for transcatheter procedures, which are being performed increasingly in outpatient care.

Europe

• The European Society of Cardiology (ESC) has changed its guidelines and recommends transcatheter aortic valve replacement (TAVR) for lower risk patients, thereby increasing the patient population.
• Germany and France, for example, are in the forefront of the transcatheter era, mainly due to the robust health systems and the favorable reimbursement system for the new therapies.
• The European Union has actively funded research projects to develop transcatheter techniques, which is expected to accelerate innovation and facilitate patient access to these treatments.

Asia-Pacific

• China's transcatheter market is expanding rapidly. Local companies such as Microport and Lifetech are developing new devices to meet the needs of the Asian population.
• Japan is preparing to approve transcatheter devices faster, which will facilitate their introduction into the market.
• In the past few years, the number of heart attacks has risen in the country due to the increase in the number of cases of lifestyle diseases. As a result, there has been an increase in the number of cardiac procedures.

MEA

• The Gulf Cooperation Council countries are investing in advanced medical devices to improve the quality of care for the region’s patients, including transcatheter devices.
• The establishment of cardiac centres in the United Arab Emirates and in Saudi Arabia has facilitated the availability of these procedures and attracted patients from neighboring countries.
• It is in this context that the regulatory framework is evolving, with initiatives aimed at improving access to medical technology. This is expected to facilitate the use of transcatheter solutions.

Latin America

• Brazil is a major market for transcatheter valves, as hospitals have adopted TAVR due to the favourable reimbursement policy.
• The collaborations between local and international companies such as the one between the Brazilian hospitals and the Abbott group, for example, are driving innovation and increasing access to transcatheter devices.
• The growing awareness of the public of the importance of early intervention in heart disease and the growing importance of the use of transcatheter procedures in the region are creating a greater demand for these procedures.

Did You Know?

“Transcatheter aortic valve replacement (TAVR) has been shown to reduce hospitalization by up to 50 percent compared to surgery, which is why many patients prefer this procedure.” — American College of Cardiology

Segmental Market Size

The Transcatheter Market, especially with regard to Transcatheter Aortic Valve Replacement (TAVR) and other minimally invasive procedures, is experiencing considerable growth. It is an important response to the increasing prevalence of cardiovascular disease, especially in the aging population. In addition, technological progress has made it possible to enhance the safety and efficacy of these procedures, which is also reflected in the growing preference for less invasive treatment options among both patients and physicians.

In the field of transcatheter angioplasty the development has now reached a stage of maturity, and the major companies Edwards Lifesciences and Medtronic are concentrating their efforts on the further development and application of these techniques. North America and Europe are in the vanguard, and the successful examples of hospitals that have successfully introduced the new technology into their everyday clinical practice are well known. Transcatheter aortic valve replacement and transcatheter mitral valve repair are particularly significant examples of the success of these procedures in improving patient outcomes. And the macro-developments of the increased focus on the patient and the support of the authorities for the introduction of new therapies will continue to promote this development. 3D imaging and robot-assisted procedures will continue to influence the evolution of this field.

Future Outlook

From 2024 to 2032, the Transcatheter Market is expected to grow at a robust CAGR of 16.64%. The rising penetration of transcatheter procedures is expected to increase from around 15% in 2024 to over 40% in 2032. The rising prevalence of CVDs, along with an aging population, is expected to drive the demand for less invasive treatment options, which in turn is expected to drive the transcatheter market.

TECHNOLOGICAL ADVANCEMENTS SUCH AS the development of new transcatheter heart valves and improved delivery systems are expected to further drive the market. The advancements in diagnostics and minimally invasive surgery are improving the outcomes of these procedures and patient safety, which makes these procedures more attractive to both physicians and patients. Also, supportive policies and reimbursements are expected to enable wider access to these advanced therapies, which will contribute to market growth.

Artificial intelligence, in the planning and monitoring of procedures and in the management of patients, is destined to revolutionize the transcatheter landscape. With the emergence of personalization as a priority for health systems, the ability to adapt transcatheter interventions to the profile of each patient will become a key differentiator. In short, the transcatheter market is on the right track, driven by a combination of the changing needs of patients, technological innovations, and evolving health policies. It is becoming a key segment of the overall cardiovascular devices market.